First line immunotherapy combination fails to improve overall survival in lung cancer
ESMO Immuno-Oncology Congress, Dec. 13-16, Geneva, SwitzerlandCredit: © European Society for Medical Oncology Geneva, Switzerland, 13 December 2018 - First line immunotherapy with durvalumab or...










